An Israeli study has identified TRIM63 as a significant genetic contributor to hypertrophic cardiomyopathy (HCM)—the most ...

When heart muscle gets damaged, the result is often permanent. Unlike other muscles in the body, the heart has long been ...

This important study explored a molecular comparison of smooth muscle and neighboring fibroblast cells found in lung blood vessels afflicted by a disease called pulmonary arterial hypertension. In ...

This file photo taken at the University of Osaka in Suita, Osaka Prefecture, in January 2024, shows a cardiac muscle sheet made from iPS cells. (Kyodo) OSAKA (Kyodo) -- A startup in Tokyo on ...

the CNIC team developed a gene therapy using adeno-associated viruses (AAV)—a safe delivery system for human patients—to deliver a functional copy of TMEM43 directly into the cardiac muscle ...

Under specific 3D culture conditions, the myoblasts self-assembled into SkMO and differentiated further into other mature muscle cell types. Price also identified cells that lacked the myoblast marker ...

It has been shown that the regulation of the extracellular matrix via cardiac fibroblasts plays a major role in ... of proinflammatory genes through endothelin in vascular smooth muscle cells (VSMCs).

causing first physiologic then pathologic cardiac hypertrophy 10,12. Prolongation of functional regeneration in senescent MLC/mIgf-1 muscle also reflects increased satellite cell proliferative ...

IT is well known that glycogen is utilized during muscular work, but there is very little information available about the resynthesis of glycogen after exhaustive exercise. Goldstein 1 has shown ...

Xu hypothesized that heart cells ... heart muscle cells into tissue-like structures. Insight gained from the team's space-based research could significantly advance methods to produce cardiac ...

A scientific technique that rapidly increases the body's production of anti-inflammatory cells promoted healing ... potentially be used to repair heart muscle damage after a heart attack and ...

the company’s neonatal cardiac progenitor cell (nCPC) therapy, for the treatment of Heart Failure with Preserved Ejection Fraction (HFpEF).